Exact Sciences Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Exact Sciences.

Exact Sciences Co. (NASDAQ:EXAS) issued its earnings results on Tuesday, July, 27th. The medical research company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.31. The medical research company earned $434.82 million during the quarter, compared to analysts' expectations of $418.76 million. Exact Sciences had a negative net margin of 50.52% and a negative trailing twelve-month return on equity of 8.93%.
View Exact Sciences' earnings history.

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EXAS shares have increased by 79.9% and is now trading at $103.99.
View which stocks have been most impacted by COVID-19.

Exact Sciences issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.71 billion-$1.75 billion, compared to the consensus revenue estimate of $1.72 billion.

16 brokers have issued twelve-month target prices for Exact Sciences' shares. Their forecasts range from $120.00 to $180.00. On average, they anticipate Exact Sciences' share price to reach $151.06 in the next twelve months. This suggests a possible upside of 45.3% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Repligen (RGEN), Novavax (NVAX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of EXAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.51%), Vanguard Group Inc. (8.96%), ARK Investment Management LLC (6.24%), Baillie Gifford & Co. (2.60%), Sumitomo Mitsui Trust Holdings Inc. (2.18%) and Nikko Asset Management Americas Inc. (1.89%). Company insiders that own Exact Sciences stock include Canada Pension Plan Investment, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Edmond DE Rothschild Holding S.A., Natixis, Victory Capital Management Inc., Ikarian Capital LLC, American Century Companies Inc., Artisan Partners Limited Partnership, Perceptive Advisors LLC, and Perceptive Advisors LLC. Company insiders that have sold Exact Sciences company stock in the last year include Canada Pension Plan Investment, Graham Peter Lidgard, Jacob A Orville, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

EXAS stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Price T Rowe Associates Inc. MD, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vanguard Group Inc., Susquehanna International Group LLP, Legal & General Group Plc, and Geode Capital Management LLC.
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $103.99.

Exact Sciences has a market capitalization of $17.88 billion and generates $1.49 billion in revenue each year. The medical research company earns $-848,530,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

Exact Sciences employs 5,000 workers across the globe.

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..

Exact Sciences was founded in 1995.

The official website for Exact Sciences is www.exactsciences.com.

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at (608) 284-5700 or via email at [email protected].